Andrew D Dick Selected Research

Intermediate Uveitis (Chronic Cyclitis)

1/2021	Long-Term Safety and Efficacy of Adalimumab in Patients with Noninfectious Intermediate Uveitis, Posterior Uveitis, or Panuveitis.
1/2017	Effect of Adalimumab on Visual Functioning in Patients With Noninfectious Intermediate Uveitis, Posterior Uveitis, and Panuveitis in the VISUAL-1 and VISUAL-2 Trials.
9/2016	Adalimumab in Patients with Active Noninfectious Uveitis.
1/2013	Tumor necrosis factor polymorphisms associated with tumor necrosis factor production influence the risk of idiopathic intermediate uveitis.
5/2007	Nonsteroidal drugs for the treatment of noninfectious posterior and intermediate uveitis.
5/2005	Cyclosporine vs tacrolimus therapy for posterior and intermediate uveitis.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Andrew D Dick Research Topics

Disease

63	Uveitis 10/2021 - 11/2004
57	Inflammation (Inflammations) 01/2022 - 07/2002
12	Macular Degeneration (Age-Related Maculopathy) 09/2022 - 01/2010
10	Necrosis 01/2021 - 11/2004
9	Posterior Uveitis 01/2021 - 06/2004
8	Choroidal Neovascularization 11/2020 - 09/2013
8	Juvenile Arthritis (Juvenile Idiopathic Arthritis) 03/2020 - 11/2007
7	Panuveitis 01/2021 - 06/2011
6	Intermediate Uveitis (Chronic Cyclitis) 01/2021 - 05/2005
6	Ganglion Cysts (Ganglion) 11/2020 - 11/2002
6	Infections 01/2016 - 07/2010
6	Autoimmune Diseases (Autoimmune Disease) 05/2015 - 11/2005
5	Glaucoma 09/2022 - 03/2016
4	Retinal Degeneration 09/2022 - 05/2003
4	Diabetic Retinopathy (Retinopathy, Diabetic) 09/2022 - 04/2010
4	Body Weight (Weight, Body) 01/2019 - 01/2014
4	Hypoxia (Hypoxemia) 01/2019 - 09/2010
4	Eye Diseases (Eye Disease) 01/2018 - 04/2013
3	Blindness (Hysterical Blindness) 01/2022 - 03/2016
3	Macular Edema 01/2021 - 06/2004
3	Multiple Sclerosis 10/2017 - 02/2012
3	Cataract (Cataracts) 03/2016 - 08/2003
3	Disease Progression 07/2014 - 12/2008
3	Behcet Syndrome (Behcet's Syndrome) 04/2013 - 11/2007
2	Scleritis (Episcleritis) 01/2021 - 01/2021
2	Granulomatosis with Polyangiitis (Wegener's Granulomatosis) 01/2021 - 01/2010
2	Retinal Diseases 09/2019 - 05/2013
2	Multifocal Choroiditis 01/2018 - 06/2011
2	Graves Ophthalmopathy 01/2018 - 01/2008
2	Anterior Uveitis 04/2016 - 08/2013
2	Arthritis (Polyarthritis) 03/2016 - 01/2014
2	Neurodegenerative Diseases (Neurodegenerative Disease) 11/2015 - 06/2004
2	Neuroblastoma 01/2010 - 06/2008
1	Refractive Errors (Refractive Error) 11/2020
1	Ocular Hypertension (Glaucoma, Suspect) 01/2020
1	Papilledema 01/2019

Drug/Important Bio-Agent (IBA)

24	Retinaldehyde (Retinal)IBA 09/2022 - 08/2003
16	Adalimumab (Humira)FDA Link 01/2021 - 11/2007
12	Adrenal Cortex Hormones (Corticosteroids)IBA 01/2021 - 01/2009
10	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 01/2017 - 07/2002
8	Pharmaceutical PreparationsIBA 01/2021 - 12/2007
8	Methotrexate (Mexate)FDA LinkGeneric 03/2020 - 08/2013
8	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 09/2019 - 09/2010
8	Biological ProductsIBA 08/2018 - 05/2007
7	CytokinesIBA 08/2013 - 03/2003
6	Infliximab (Remicade)FDA Link 01/2021 - 06/2007
6	SteroidsIBA 01/2018 - 05/2007
6	Interleukin-10 (Interleukin 10)IBA 01/2013 - 08/2005
5	Complement System Proteins (Complement)IBA 01/2022 - 01/2010
5	Immunosuppressive Agents (Immunosuppressants)IBA 10/2017 - 05/2007
5	Proteins (Proteins, Gene)FDA Link 09/2017 - 06/2004
5	Prednisone (Sone)FDA LinkGeneric 09/2016 - 05/2007
5	Tacrolimus (Prograf)FDA LinkGeneric 06/2012 - 05/2005
4	EndotoxinsIBA 01/2019 - 11/2015
4	Fluorescein (Funduscein)FDA LinkGeneric 04/2018 - 01/2010
4	Monoclonal AntibodiesIBA 01/2017 - 05/2011
4	Cyclosporine (Ciclosporin)FDA LinkGeneric 03/2015 - 05/2005
3	AntibodiesIBA 11/2021 - 08/2013
3	Interleukin-33IBA 11/2020 - 02/2015
3	C-Reactive ProteinIBA 01/2020 - 03/2016
3	Interleukin-6 (Interleukin 6)IBA 09/2019 - 01/2017
3	AntigensIBA 01/2018 - 09/2008
3	Peptides (Polypeptides)IBA 05/2015 - 11/2002
2	EpitopesIBA 11/2021 - 10/2015
2	Immunologic Factors (Immunomodulators)IBA 10/2021 - 09/2016
2	Immunomodulating AgentsIBA 01/2021 - 01/2018
2	Tumor Necrosis Factor InhibitorsIBA 01/2021 - 03/2020
2	Particulate MatterIBA 11/2020 - 11/2019
2	tocilizumab (atlizumab)FDA Link 03/2020 - 01/2018
2	LipopolysaccharidesIBA 01/2019 - 07/2010
2	Bevacizumab (Avastin)FDA Link 04/2018 - 08/2013
2	Oxygen (Dioxygen)IBA 01/2017 - 09/2008
2	GlucocorticoidsIBA 09/2016 - 12/2007
2	Antinuclear AntibodiesIBA 03/2016 - 01/2014
2	Sirtuin 1IBA 05/2015 - 05/2013
2	Interleukin-17 (Interleukin 17)IBA 07/2014 - 04/2013
2	LigandsIBA 06/2014 - 01/2012
2	InterferonsIBA 04/2014 - 05/2007
2	Protein Isoforms (Isoforms)IBA 09/2013 - 08/2013
2	Fingolimod Hydrochloride (FTY720)FDA Link 02/2012 - 10/2008
2	RNA-Binding Proteins (RNA-Binding Protein)IBA 11/2010 - 07/2010
2	Phosphorus (Red Phosphorus)IBA 01/2010 - 06/2008
1	ElastinIBA 11/2021
1	insulin receptor-related receptor (IRR)IBA 01/2021
1	Nitrogen OxidesIBA 11/2020
1	Environmental Pollutants (Pollutants, Environmental)IBA 11/2020
1	Neuropeptide YIBA 01/2020
1	Aquaporin 1IBA 01/2020
1	Fibronectins (Fibronectin)IBA 01/2020
1	Endothelial Growth FactorsIBA 09/2019
1	N-Methylaspartate (NMDA)IBA 01/2019

Therapy/Procedure

30	Therapeutics 09/2022 - 01/2004
5	Lasers (Laser) 02/2016 - 04/2010
4	Biological Therapy 10/2018 - 05/2007
3	Intravitreal Injections 10/2021 - 11/2016
3	Immunomodulation 01/2018 - 03/2016
2	Time-to-Treatment 01/2019 - 01/2017
2	Radiotherapy 01/2018 - 01/2008
2	Immunotherapy 09/2008 - 06/2004
1	Microspheres (Microsphere) 01/2020